A key opinion leader reviews the role of PI3K kinase inhibitors in the third-line or later settings for the treatment of follicular lymphoma.
Kristie L. Kahl: To bring this discussion together, can you talk about the role of the PI3K kinase inhibitors for a relapsed or refractory follicular lymphoma in the third line or earlier?
Sameh Gaballa, MD: Obviously, we have a few PI3 kinase inhibitors. The initial 1 was idelalisib. Then we got copanlisib, then duvelisib, and most recently umbralisib. They’re all approved in patients with follicular lymphoma, in the third-line setting. Although umbralisib, I believe, is for patients who’ve had 3 lines of prior therapies. In any case, efficacy-wise, most of them are similar. You’re getting overall responses anywhere between 50% and 60%. Progression-free survival is typically about a year, give or take. There are differences among them, though. They’re not all the same in terms of their safety profile. Idelalisib and duvelisib can be associated with some hepatic issues: Infectious complications such as colitis or pneumonitis in patients. Copanlisib seems to have less of these, but it’s associated with some transient elevations in blood pressure or blood glucose. Copanlisib is an infusion, whereas the others are oral. Copanlisib, being an infusion, is given intermittently, whereas others are given continuously. There are other ongoing trials looking at intermittent dosing for oral PI3 kinase inhibitors. The most recent addition has been umbralisib, which is a PI3 kinase delta isoform inhibitor. It also has fewer of these immune-mediated adverse effects, but it still has some hepatic issues, so you want to keep an eye on their liver functions. But it definitely has less autoimmune pneumonitis, in particular, which is definitely a welcome addition to the options that we have.
Transcript edited for clarity.
NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy
August 17th 2021This article reviews NCCN Guideline updates regarding the use of genomic assays in predicting the benefit of extended adjuvant endocrine therapy in patients with HR+ breast cancer and includes insights from Lee S. Schwartzberg, MD, of West Cancer Center at the University of Tennessee Health Science Center in Memphis, TN.
Individualizing Extended Adjuvant Therapy in HR+ Breast Cancer
June 15th 2021This article reviews individualizing extended adjuvant therapy for patients with HR+ breast cancer and includes insights from Vijayakrishna (V. K.) Gadi, MD, PhD, of the University of Illinois in Chicago, and Reshma L. Mahtani, DO, of the University of Miami Health System in Deerfield Beach, FL.
Advances in Later-Line Management of Relapsed/Refractory Follicular Lymphoma
May 27th 2021This article reviews advances in later-line management of relapsed/refractory follicular lymphoma. This article also features insights from oncology expert Sameh Gaballa, MD, of Moffitt Cancer Center in Tampa, Florida.